All In Biotech

Drug Trial Radar · NCT06934967

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

An Open-label, Single-arm, Multicenter, Phase 3 Study to Assess Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric PNH Patients 2 to <18 Years of Age

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Oct 28, 2025

Primary completion

Oct 14, 2031

Study completion Nov 13, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this open-label, single arm, multicenter, phase 3 study is to assess the pharmacokinetics of iptacopan in pediatric patients and to assess whether iptacopan is safe and well tolerated when used for the treatment of pediatric paroxysmal nocturnal hemoglobinuria (PNH) patients 2 to \< 18 years of age.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

  • LNP023Drug

    Cohort 1-administered orally a dosing scheme of 200 mg twice-daily (two 100 mg capsules). Cohort 2- administered orally a dosing scheme based on weight at the Day 1, Week 12, 26 and 38.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 26 weeks
  2. PK parameter (Cmax)Time frame: Week 2
  3. PK parameter (AUClast)Time frame: Week 2
  4. PK parameter (AUCtau)Time frame: Week 2
  5. PK parameter (Ctrough)Time frame: Weeks 2, 4, 12 and 26

Locations

15 sites in 6 countries. Site status is shown where the registry gives one.

  • Childrens Healthcare of Atlanta

    Atlanta, Georgia · Recruiting

  • Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • St Jude Childrens Research Hospital

    Memphis, Tennessee · Recruiting

  • Novartis Investigative Site

    Brasília, Federal District, Brazil · Recruiting

  • Novartis Investigative Site

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Novartis Investigative Site

    Santo André, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany · Recruiting

  • Novartis Investigative Site

    Genova, GE, Italy · Recruiting

  • Novartis Investigative Site

    Utrecht, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.